A selection of senior appointments during Quarter 3, 2019 across EMEA. Industry segments this quarter included Artificial Intelligence, CNS, Animal Health, Immunology, Gene Therapy, Diagnostics, Precision Medicine, Vaccines and Antimicrobials.
EVENTS
23 January
2020
The popular BIA Gala Dinner returns this coming January. Join us in London for the premier bioscience networking event of the year, with up to 700 life science professionals from over 300 biotech companies, investors, government and the media. Meet old friends and make new business contacts.
EVENTS
28 January
2020
Join us at this New Year’s event for an update on progress in personalised medicine. flanders.health will present a couple of start-up and scale-up companies from different technological fields, active in the health ecosystem. See you there!
Coulter Partners was delighted to partner recently with Azitra Inc. and secure the appointment of Mark Sampson, Ph.D. as their Chief Scientific Officer. Azitra is a clinical-stage medical dermatology company addressing severe skin conditions by harnessing the microbiome and has just announced that it has closed a $14 million Series A financing, led by KdT Ventures in conjunction with existing investor Bios Partners. EVENTS
4 February - 5 February
2020
Meet us in February in London for the sixth annual LSX World Congress. This event brings together the executives that matter to the future of healthcare and life science business strategy, investment, partnering, deal making and commercialisation. See you there!
Edward Hæggström, CEO of Nanoform said: “It gives me great pleasure to welcome Mads Laustsen to the Nanoform board. Mads is an exceptional entrepreneur with vast experience in the provision of GMP facilities and infrastructures. His outstanding experience will be incredibly valuable as we expand our manufacturing capacity and I thank the highly professional team at Coulter Partners for helping us once more to achieve such a quality appointment.”EVENTS
5 February
2020
On June 25, Coulter Partners hosted around 200 guests for a sparkling Summer Party in the beautiful gardens of the Walks, Gray’s Inn, London. International clients and colleagues joined the London team in the big marquee to celebrate a fabulous year!
“We are pleased that Ms. Beelen has joined Incysus at this key phase of development and thank the team at Coulter Partners for their outstanding professional support in achieving this appointment,” said William Ho, Chief Executive Officer of Incysus. “Melissa’s more than two decades of experience in drug development and clinical research will be invaluable as we take the next steps to develop commercially viable and effective allogeneic cellular immunotherapies for the treatment of cancer.”
In April Samantha Bower and Mat Rosso, two of Coulter Partners’ Pittsburgh team, ran far from home in their first London Marathon in aid of London based charity, Kith and Kids. Samantha came home in a truly athletic 2 hours and 57 minutes and was the 81st woman to cross the line!!! In his first ever marathon, former US professional figure skater, Mat completed the race in 4 hours and 40 minutes.
OxStem Co-Founder, Director and Waynflete Professor of Chemistry at the University of Oxford, Professor Steve Davies, said: “On behalf of the Board, Founders and management team, we warmly welcome Dr Stuart Collinson to OxStem and I thank the team at Coulter Partners for their outstanding professional support in achieving this appointment. Stuart is a highly experienced international business leader who brings significant fundraising, product development, partnering and commercialisation experience. We look forward to working with him to develop transformative medicines for patients suffering from severe degenerative diseases."
Global Life Sciences search specialist, Coulter Partners is pleased to announce the opening of a new office in Paris and another 14 appointments worldwide, during an extremely successful year which has seen group sales grow by 31%. Business in the US has grown by 165% since last year and this region now accounts for 45% of group sales.
“We were delighted to work once more with Coulter Partners to identify Christa and bring her into Pivot Bio. Her experience is a great addition to our already strong leadership team,” said Karsten Temme, CEO and co-founder, Pivot Bio. “Christa will play a key role in Pivot’s growth as we expand the technology to new markets.”
Dr John Ford, CEO, Enterprise Therapeutics, said: “We are delighted that Amit has chosen to join as Chairman at this exciting time for the Company, as we prepare to take our two lead programmes into the clinic in the next 12 months. Amit brings a wealth of experience in product development, portfolio management and commercial strategy in both the US and EU that will be critical in driving the Company through the next phase of its development. I would like to thank the team at Coulter Partners for their outstanding professional support in achieving this high calibre appointment.”
“We are very pleased to welcome Carla to AniCura. Her profound experience of building a strong healthcare group with efficient support to individual clinics will be key to developing AniCura, as we have now grown to become a leading veterinary care provider with more than 1,200 employees in the region. I would also like to express my sincere thanks to the team at Coulter Partners for their outstanding professional support in achieving this high calibre appointment,” says Øyvind Johnsen Brøgger, Group Operations Director at AniCura.
As a member of the Association of Executive Search and Leadership Consultants, Coulter Partners is proud to commit to a Code of Professional Practice. This video explains the value the AESC brings to our profession.
Coulter Partners was very pleased to partner with ArunA Bio, a leader in the development of exosomes for the treatment of CNS and neurodegenerative disorders, to secure the appointment of Mark Sirgo, Pharm.D. as Chief Executive Officer. Dr. Sirgo joins the company with more than 35 years of pharmaceutical industry experience and is most recognized for building the fully integrated pharmaceutical company, BioDelivery Sciences International (Nasdaq: BDSI).